Agios Pharmaceuticals, Inc. (LON:0HB0)
27.30
-0.20 (-0.73%)
At close: Dec 5, 2025
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.88M USD in the quarter ending September 30, 2025, with 43.69% growth. This brings the company's revenue in the last twelve months to $44.79M, up 36.26% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$44.79M
Revenue Growth
+36.26%
P/S Ratio
36.42
Revenue / Employee
$91.78K
Employees
488
Market Cap
1.21B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Agios Pharmaceuticals News
- 10 days ago - Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO Stock News - GuruFocus
- 12 days ago - Truist Securities Initiates Coverage on Agios Pharmaceuticals (AGIO) with a 'Buy' Rating | AGIO ... - GuruFocus
- 17 days ago - This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
- 17 days ago - Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
- 17 days ago - Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Trial Results - GuruFocus
- 17 days ago - Noteworthy Wednesday Option Activity: AGIO, VLO, AMTM - Nasdaq
- 17 days ago - Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility - Seeking Alpha
- 17 days ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript - Seeking Alpha